摘要
背景:DNA拓扑异构酶家族由一组催化DNA拓扑变化的酶组成。这些酶在细胞复制机制中起着重要作用,因此,抗癌药物的重要靶点-人类DNA拓扑异构酶IIα是其中最突出的靶点之一。针对这种酶的活性化合物可分为潜水员两类。硒的作用机制:DNA毒物通过稳定DNA和拓扑异构酶之间的共价裂解复合物,将其转化成细胞毒素而起作用,而第二组不同的c由于DNA中毒治疗过程中经常出现副作用,因此,atalytic抑制剂为解决这种酶提供了新的抑制途径。 方法:在综合文献研究的基础上,本文综述了现有的生物分析方法和硅胶法在人体拓扑异构酶IIα抑制剂鉴定中的应用。 结果与结论:全面概述了详细探讨拓扑异构酶IIα抑制bo的体外机制和功能的现有方法和途径。提出了TH拓扑II型α抑制剂基团。利用体外细胞试验和体内研究,进一步探索药物临床前阶段有效的topoⅡα抑制剂。对发现进行了讨论。概述了IN硅法在拓扑异构酶Ⅱα抑制剂发现中的应用前景。编制了一份实用指南清单,以帮助新的、经验丰富的研究员。如何在临床前药物开发阶段优化设计靶向抑制剂和验证。
关键词: 人dna拓扑异构酶IIα,催化抑制剂,脱氧核糖核酸毒物,抗癌药物,生物分析,药物化学。
Current Medicinal Chemistry
Title:Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors
Volume: 25 Issue: 28
关键词: 人dna拓扑异构酶IIα,催化抑制剂,脱氧核糖核酸毒物,抗癌药物,生物分析,药物化学。
摘要: Background: The family of DNA topoisomerases comprises a group of enzymes that catalyse the induction of topological changes to DNA. These enzymes play a role in the cell replication machinery and are, therefore, important targets for anticancer drugs - with human DNA topoisomerase IIα being one of the most prominent. Active compounds targeting this enzyme are classified into two groups with diverse mechanisms of action: DNA poisons act by stabilizing a covalent cleavage complex between DNA and the topoisomerase enzyme, transforming it into a cellular toxin, while the second diverse group of catalytic inhibitors, provides novel inhibition avenues for tackling this enzyme due to frequent occurrence of side effects observed during the DNA poison therapy.
Methods: Based on a comprehensive literature search we present an overview of available bioassays and in silico methods in the identification of human DNA topoisomerase IIα inhibitors.
Results and Conclusion: A comprehensive outline of the available methods and approaches that explore in detail the in vitro mechanistic and functional aspects of the topoisomerase IIα inhibition of both topo IIα inhibitor groups is presented. The utilized in vitro cell-based assays and in vivo studies to further explore the validated topo IIα inhibitors in subsequent preclinical stages of the drug discovery are discussed. The potential of in silico methods in topoisomerase IIα inhibitor discovery is outlined. A list of practical guidelines was compiled to aid new as well experienced researchers in how to optimally approach the design of targeted inhibitors and validation in the preclinical drug development stages.
Export Options
About this article
Cite this article as:
Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors, Current Medicinal Chemistry 2018; 25 (28) . https://dx.doi.org/10.2174/0929867325666180306165725
DOI https://dx.doi.org/10.2174/0929867325666180306165725 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements